~~<i id='136F902898'><strike id='136F902898'><tt id='136F902898'><pre id='136F902898'></pre></tt></strike></i>~~

Home» leisure time» comprehensive

comprehensive

author：Wikipedia 2025-10-02 07:58:46 Page View：94456

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： EU regulator recommends expanding Mounjaro approval to obesity
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

MollyFerguson/STATHello!SometakesandthoughtsonGilead’sTrodelvytroubles,ElevationOncology’ssurprising

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

0:58FormerPresidentDonaldTrumppausesforcheersfromthecrowdbeforespeakingasthekeynotespeakeratthe56thA